Bonavida Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy

2008
ISBN: 978-1-59745-474-2
Verlag: Humana Press
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 431 Seiten, eBook

Reihe: Cancer Drug Discovery and Development

This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Bonavida, Benjamin

Inhaltsverzeichnis

Table of Contents

Preface
Part I. Sensitization via membrane-bound receptors
1. Sensitization of epithelial cancer cells with human monoclonal antibodies
Peter Vollmers and Stephanie Brandlein
2. Targeting the transferrin receptor to overcome resistance to anti-cancer agents
Tracy R. Daniels, Isabel I. Neacato, Gustavo Helguera, Manuel L. Penichet
3. Chemo-immunosensitization of resistant B-NHL as a result of rituximab (anti CD20 mAb)-mediated inhibition of cell survival signaling pathways
Benjamin Bonavida, Ali R. Jazirehi, Mario I. Vega, Sara Huerta-Yepez, Kazuo Umezawa, and Eriko Suzuki
4. Agents that regulate DR5 and sensitivity to TRAIL
Tatsushi Yoshida and Toshiyuki Sakai
5. Proteasome inhibition: Potential for sensitization of immune effector mechanisms in cancer
Milad Motarjemi, William H.D. Hallett, Minghui Li, and William J. Murphy

Part II. Sensitization via inhibition of cell survival pathways (excluding apoptotic signaling pathways)
6. Angiogenesis inhibitors as chemosensitizing agents for the treatment of metastatic disease
Giulio Francia, Urban Emmenegger, and Robert S. Kerbel.
7. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK and P13K/Akt pathways to sensitize cancer cells to therapy
James A. McCubrey, Richard A. Franklin, Fred E. Bertrand, Jackson R. Taylor, illiam H. Chappell, Melissa L. Midgett, Ellis WT. Wong, Stephen L. Abrams, ristin M. Stadelman, Negin Misaghian, Dale E. Lugwid, Jorg Basecke, Massimo ibra, Franca Stivala, Michele Milella, Agostino Tafuri, Alberto M. Martelli, aolo Lungi, Antonio Bonati, David M. Terrian, Brian D. Lehmann, and Linda S. Steelman
8. Histone deacetylase inhibitors and anti-cancer activity
Roberto R. Rosato and Steven Grant
9. Eicosanoids and resistance of cancer cells to chemotherapeutic agents

Andrey Sorokin

Part III. Sensitization via transcription factors

10. The RKIP and STAT3 axis in cancer chemotherapy: opposites attract
Devasis Chatterjee, Edmond Sabo, Murray B. Resnick, Kam C. Yeung, and Y. Eugene Chin
11. Targeting transcription factors with decoy oligonucelotides: modulation of the expression of genes involved in chemotherapy resistance of tumor cells
Roberto Gambari
12. p53 inhibitors as cancer sensitizing agents
Flavio Maina and Rosanna Dono
13. Nitric Oxide-Induced Immunosensitization to Apoptosis by Fas-L and TRAIL
Benjamin Bonavida, Sara Huerta-Yepez, Mario I. Vega, Demetrios A. Spandidos and Stravoula Baritaki
14. Natural agents that can sensitize tumor cells to chemotherapy and radiation therapy
Ganesh Jagetia, Sunil Krishnan, and Bharat B. Aggarwal

Part IV. Sensitization via targeting apoptotic pathways
15. Inhibitors of the Bcl-2 protein family as sensitizers to anticancer agents
Daniel E. Johnson
16. Therapeutic targeting of apoptosis in cancer
Timothy R. Wilson, Daniel B. Longley, and Patrick G. Johnston
17. Peptides and peptidomimetics as cancer therapy sensitizing agents
Shantanu Banerji, Sudharsana Rao Ande, Subbareddy Maddika, Versha Banerji, Iran Rashedi, Neil W. Owens, Anne Zuse, Frank Schweizer, and Marek Los
18. Nonpeptidic mimetics as cancer sensitizing agents
Ruud P.M. Dings, Mark Klein, and Kevin H. Mayo
19. Sensitization of cancer cells to cancer therapies by isoflavone and its synthetic derivatives
Fazlul H. Sarkar and Yiwei Li
20. Antisense oligonucelotides and siRNA as specific inhibitors of gene expression: mechanisms of action and therapeutic potentitial; AS-ODN and siRNA: mechanisms and therapeutic potential
Yvonne Förster and Bernd Schwenzer
Part V. Sensitization tailored to individual patients
21. DNA